Estrogen–ER-α axis induces PNPLA3 p.I148M protein variant to promote steatotic liver disease susceptibility in women

Alessandro Cherubini; Elia Casirati; Serena Pelusi; Luca Valenti

doi:10.1002/ctm2.1524

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (1) : e1524 DOI: 10.1002/ctm2.1524

COMMENTARY

Estrogen–ER-α axis induces PNPLA3 p.I148M protein variant to promote steatotic liver disease susceptibility in women

Author information +

History +

PDF

Cite this article

Download citation ▾

Alessandro Cherubini, Elia Casirati, Serena Pelusi, Luca Valenti. Estrogen–ER-α axis induces PNPLA3 p.I148M protein variant to promote steatotic liver disease susceptibility in women. Clinical and Translational Medicine, 2024, 14(1): e1524 DOI:10.1002/ctm2.1524

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatol Baltim Md. 2023;77(4):1335-1347.

[2]	BasuRay S, Smagris E, Cohen JC, Hobbs HH. The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. Hepatol Baltim Md. 2017;66(4):1111-1124.

[3]	Meda C, Barone M, Mitro N, et al. Hepatic ERα accounts for sex differences in the ability to cope with an excess of dietary lipids. Mol Metab. 2020;32:97-108.

[4]	Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J Gastroenterol. 2012;18(3):237-243.

[5]	Sarkar MA, Suzuki A, Abdelmalek MF, et al. Testosterone is associated with nonalcoholic steatohepatitis and fibrosis in premenopausal women with NAFLD. Clin Gastroenterol Hepatol. 2021;19(6):1267-1274.e1.

[6]	Lazo M, Zeb I, Nasir K, et al. Association between endogenous sex hormones and liver fat in a multiethnic study of atherosclerosis. Clin Gastroenterol Hepatol. 2015;13(9):1686-1693.e2.

[7]

Polyzos SA, Kountouras J, Mantzoros CS, Polymerou V, Katsinelos P. Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance, non-invasive indices of steatosis and fibrosis, and adipokine levels in non-alcoholic fatty liver disease: a randomized controlled trial. Diabetes Obes Metab. 2017;19(12):1805-1809.

[8]	Stender S, Kozlitina J, Nordestgaard BG, Tybjærg-Hansen A, Hobbs HH, Cohen JC. Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet. 2017;49(6):842-847.

[9]	Cherubini A, Ostadreza M, Jamialahmadi O, et al. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women. Nat Med. 2023;29(10):2643-2655.

[10]	Cherubini A, Casirati E, Tomasi M, Valenti L. PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date. Expert Opin Ther Targets. 2021;25(12):1033-1043.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.